It was previously shown that anti-inflammatory agent or antiviral immunity enhancing agents increased survival of mice infected with mouse-adapted SARS-CoV and treated with a NF-kB inhibitor [42] or various toll-like receptor agonists [31, 42–44], which was started shortly before or after virus infection. This evidence concerns the gene NFKB1 and viral infectious disease.